The announcement came hot on the heels of announcements from Ceva and Boehringer that they too had vaccines in the pipeline.
Syvazul BTV3 is licensed to reduce viraemia, prevent mortality and reduce clinical signs and lesions in sheep and for the active immunisation against bluetongue virus serotype 3 in cattle.
Like all vaccines currently available for this serotype, the vaccine will not prevent infection and vaccinated animals will still be subject to bluetongue movement controls and trade restrictions currently in place.
Administered as a single 2ml dose subcutaneously in sheep and as two 4ml intramuscular doses 3 weeks apart in cattle, Syvazul BTV3 contains inactivated Bluetongue virus, serotype 3 (BTV-3), strain BTV-3/NET2023.
The vaccine is licenced for use during pregnancy and lactation in both sheep and cattle.
The onset of immunity is 28 days after the primary vaccine in sheep. A single booster revaccination dose of 2ml for sheep and 4ml for cattle is recommended after 12 months.
Presented in two pack sizes, 80ml and 200ml, Syvazul BTV3 vaccine has a shelf life of 2 years from manufacture and a broach life of 10 hours.
Licensing for use will be geographic, based upon high risk counties or by specific licence from the APHA.
Furosoral contains furosemide and is indicated for the treatment of hydrothorax, hydropericardium, ascites and oedema, particularly in animals where these conditions are associated with cardiac insufficiency and renal dysfunction.
Furosoral replaces Dechra’s previous diuretic treatment, Frusedale.
It is available in both 10 mg and 40 mg double-divisable tablets.
The recommended daily starting dose for cats and dogs is 2.5 mg per kg of body weight.
Dechra says careful weighing is essential to ensure accurate dosing, but that the dosage can be doubled initially for severe or particularly resistant cases and adjusted to the lowest clinically effective dose for maintenance therapy if required.
Dechra companion animal brand manager, Charlotte Hill, said: “Furosoral offers a flexible treatment solution where dosage can be adjusted, depending on the needs of the patient and the underlying causes, to give vets more options for treating cats and dogs with fluid retention.
“To ensure it is as appealing to pet owners as it is to veterinary professionals, Furosoral is available in our innovative Smart Tab format, giving owners confidence that they are giving their dog or cat the right dosage and aiding compliance, leading to better outcomes for the animal.”
Furosoral 10 mg and 40 mg tablets are available in blister packs of 100 tablets for quick and easy dispensing. Divided tablets can be stored in the blister pack for up to three days, ensuring no waste.
https://www.dechra.co.uk/products/dog/prescription#/search=furosoral/.
The webinar will cover the entire disease process of MMVD in dogs from pathology to current treatment approaches and future advancements in therapy, and will include the following presentations:
https://us06web.zoom.us/webinar/register/WN_QyfUofLgRG-YsaXQbkT7Tw#/registration
Francesca's initiative was recognised with a RCVS Knowledge ‘Highly Commended’ status at its 2024 awards.
The idea for the audit came about after Francesca noticed a trend for patients to become hypotensive during anaesthesia for routine feline neutering and need additional treatment.
CVS says clinical evidence suggests a minimum value of 60mmHg for perfusion of vital organs such as the brain, heart and kidneys.
So a clinical audit was undertaken to look at perioperative blood pressure in both cats and dogs having routine neutering procedures.
The target was for patients to maintain a mean arterial blood pressure of 60mmHg during their anaesthetic.
The animals chosen for auditing were to be classed ASA 1 and under 5 years old.
They received a pre-operative health check including a blood pressure reading to ensure they were normotensive.
A first audit looked at a standard premedication protocol of ACP at a dose rate of 0.02mg/kg combined with methadone at a dose rate of 0.3mg/kg.
A second audit initiated a change to the pre-medication drugs, using 0.005mg/kg medetomidine combined with the same dose of methadone.
Both received anaesthesia induction with Propoflo at a dose rate of 6mg/kg for cats and 4mg/kg for dogs.
All patients under anaesthetic were maintained using isoflurane and kept at a surgical plane of anaesthesia appropriate for that patient.
The patients were monitored throughout their surgical procedure using an oscilliometric monitoring machine - for systolic, diastolic and mean arterial blood pressure – and measurements recorded on an anaesthetic chart.
The collected data revealed that in the first audit, where patients received ACP and methadone, 42% (50% of cats and 38% of dogs) had a mean arterial blood pressure lower than 60mmHg after the first five blood pressure readings post induction.
In the second audit, with medetomidine combined with methadone, only 11% of patients (0% of cats and 15% of dogs) with a mean arterial blood pressure lower than 60mmHg.
In addition to the reduction in hypotensive patients during anaesthesia when the medetomidine/methadone combo was used, Francesca says the audit suggests a link to hypotension with ACP used as a premedication in anaesthetised patients.
Francesca said: “My passion in veterinary nursing is anaesthesia. And there is always room for improvement and striving to achieve gold standard care.
“These results clearly show that a change from our current premedication protocol of ACP and Methodone to Medetomidine and Methadone decreased the number of patients having hypotension during anaesthesia. The change means fewer patients were at risk of developing the side effects associated with hypoperfusion of the vital organs.
“Our quality improvement initiative has made a really positive impact in practice for both patient care and clinical team.”
In the study: "Effects of human-animal interaction on salivary and urinary oxytocin in children and dogs1", oxytocin levels were recorded in 55 children and their pet dogs.
Oxytocin is associated with positive emotions, the reduction of stress and the formation of social bonds.
Oxytocin levels were tracked in both the children’s and dogs’ urine and saliva before and after they interacted.
Researchers say this is one of the first studies to examine the benefits of human animal interactions for both humans and dogs.
For the study, the children's oxytocin levels were measured when they interacted with their own pet dog, with an unfamiliar dog (a trained therapy dog), and when they engaged in solitary play.
The study found that:
The researchers concluded that the results support the hypothesis that oxytocin pathways may shape and respond to social interactions between children and dogs, highlighting an important role for companion animals in child development.
https://www.waltham.com/oxytocin-children-and-dogs
Reference
The materials include pet owner guides, reception posters and slides to display on waiting room TV.
They complement the Krka veterinary professional guide on responsible risk-based parasiticide use for cats and dogs that was developed in conjunction with Ian Wright BVMS MSc MRCVS and launched last year.
Renzo Di Florio, Krka’s Technical Veterinary Adviser said: “In first opinion veterinary practice, where the majority of consultations last 15 minutes or less, time is short and in-depth discussions are not always possible.
"The guides provide comprehensive information on common parasites, practical advice on prevention and treatment and information on risk assessment.
"And by aligning with ESCCAP guidelines, the guides help address the delicate balance between animal health, human health and environmental protection – a true One Health issue.”
https://www.krka.co.uk/veterinary-knowledge-hub/articles/risk-based-parasiticide-use-for-cats-and-dogs
Zoetis says the Vetscan OptiCell represents a significant leap forward in technology and offers meaningful time, cost and space savings for veterinary healthcare teams, contributing to better patient outcomes and a more efficient clinic workflow.
It uses cell-focusing and AI-powered classification technology for CBC analysis, delivering a claimed lab quality accuracy at the point of care.
Dr. Richard Goldstein, DVM, DACVIM, DECVIM-CA, Global Chief Medical Officer and Head of Medical Affairs at Zoetis said: “Vetscan OptiCell delivers high-quality results, enables improved efficiency, and provides a compact footprint.
"For the first time, we are able to use advanced AI image recognition technology to characterise the blood cells instead of relying on their size or other physical parameters.”
Pre-orders will be available in the UK later this year.
The awards fall into two categories, those which you need to be nominated for by other people and those which are also open to self-nomination:
Requiring nomination by another person:
Self-nominations allowed:
The deadline for the 2025 awards is Friday, 13 December 2024.
https://www.rcvs.org.uk/how-we-work/rcvs-honours-awards
The films, which include information and practical advice based on the pillars of lifestyle medicine and the neuropsychology of hormones, are aimed both at individuals who are directly affected and those who want to support them.
Wellvet co-founder Liz Barton said: “We now know that nearly half of veterinary team members experience a moderate-severe impact of perimenopause symptoms on their mental health, and a third report a significant impact on their working life and career."
Dr. Claire Gillvray, GP, Lifestyle Medicine specialist and psychiatrist with a special interest in women’s health, who introduces the films, said: “While we tend to focus on the individual, we all have friends, family, colleagues and clients who will experience symptoms impacting their mental and physical health and relationships.
"Although some women transition through the menopause with no problems, many women suffer a multiplicity of debilitating symptoms.
"These symptoms can be devastating and the medical advice they receive can be extremely variable, with some doctors dismissing perimenopause.
"Though onset can be earlier, symptoms typically occur between the ages of 40-60 years and can last for a decade or more, and there can be severe health impacts including cardiovascular, neurological and orthopaedic disease."
“These videos will empower individuals to take control of their symptom monitoring, have meaningful conversations with medical professionals, and trial lifestyle adjustments that may improve their health and wellbeing.”
The first instalment of nine 5-30 minute bitesize videos are accessible now on the WellVet website: https://www.wellvet.co.uk/resources/menopause-resources-for-veterinary-teams/.
The award categories are:
Nominations are welcome from both BSAVA members and non-members.
Nominations close on 30th October 2024 and the winners will be announced on 16th January 2025.
The BSAVA awards ceremony will take place at the reinvented Congress and Expo 2025, taking place at Manchester Central in March.
https://www.bsava.com/awards.
The talk, which is sponsored by Supreme Petfoods, will be co-delivered by Craig Tessyman, who works alongside Molly as Exotics Veterinary Nurse Team Leader at Rutland House Veterinary Referrals.
The presentation will focus on the main aspects of emergency care, including best practice for managing these cases in first opinion practice.
Topics will include restoring and maintaining fluid balance, cardio-pulmonary resuscitation (CPR), analgesia options and the importance of appropriate monitoring.
Molly said: “The basic principles of emergency care apply to all species, but with small herbivores, rapid intervention is crucial as their delicate physiology can quickly spiral into crisis when they become unwell.
"In this session, Craig and I will share practical tips that vets and nurses can implement immediately, without requiring specialist equipment, to help manage these challenging cases.”
The sixty minute talk will start at 12.50pm in the Gallery Suite 3-4.
For those unable to attend the live event, a recorded version of the presentation will be available here: https://supremepetfoods.com/vet-zone/cpd-webinars-and-videos/
Ms Parody faced two charges, the first of which related to her treatment of a cat named Shadow and had multiple elements:
The second charge was that her conduct in relation to all parts of the first charge was dishonest.
At the outset of the hearing Ms Parody’s counsel admitted to the majority of the elements of the first charge, although denied she had removed the microchip in order to mislead others about Shadow’s identity.
Ms Parody also admitted that her failures to inform the owner that euthanasia had not been carried out, of the treatment plan, of the removal of the microchip and that she had taken Shadow home was dishonest.
However, she denied dishonesty in relation to failing to make adequate records.
The Committee went on to consider the facts of the remaining, contested charges.
After hearing evidence from a number of witnesses, the Committee concluded that it was not proven that Dr Parody removed the microchip in order to mislead others about his identity, and that, in this respect, she had therefore not acted dishonestly.
In relation to whether Ms Parody was acting dishonestly in relation to failure to make adequate clinical records, the Committee also found this not proven.
Having determined the facts of the case, the Committee went on to consider if the proven charges amounted to serious professional misconduct.
In terms of aggravating factors, it considered that there was actual injury to an animal – albeit small and while the cat was under sedation - and that Ms Parody had engaged in conduct that was in breach of a client’s trust.
In mitigation, the Committee considered the immense pressure that Ms Parody and her colleagues in the practice were under at that time due to the coronavirus pandemic and the fact that she had acted in a way which she thought was best for Shadow’s welfare and which clouded the rest of her decision making.
Furthermore, the Committee considered this was a single isolated incident, that she took the decision without the opportunity for full reflection and the length of time since the original incident.
However, it found Ms Parody guilty of serious professional misconduct in relation to all the proven charges.
Paul Morris, chairing the Committee and speaking on its behalf, said: “However well-intentioned, Dr Parody made some serious errors of judgment with regard to her approach to Shadow and embarked upon a course of dishonest conduct, which started with her failure to inform the owner about her decision not to euthanase Shadow, was followed by her treatment of Shadow, including his castration and microchip removal, all without the consent of the owner, and ended with her taking Shadow home over Christmas, again without the owner’s consent.
"In addition, she failed to make adequate clinical records with regards to Shadow.”
The Committee then went on to consider the most appropriate sanction for Ms Parody.
It heard a large number of positive testimonials as to her character and professionalism from both clients and former and current work colleagues.
The Committee also considered further mitigating factors such as the fact she had no previous disciplinary issues, had a long and unblemished career both before and since this isolated incident, her open and frank admissions regarding some of the charges, the significant impact she displayed regarding her misconduct, and her genuine expressions of remorse and apology.
Paul Morris added: “The Committee recognises that there is a scale of seriousness of dishonesty and therefore gave careful consideration as to where Dr Parody’s dishonest conduct fell to be judged.
"The Committee was concerned with her conduct between 20 December and 31 December 2021, as found proved.
"What led to what she has admitted as dishonest behaviour, was her acting to protect the welfare of the cat.
“The Committee was confident that she most certainly did not set out to act dishonestly.
"She made an initial error of judgement and everything that followed flowed from that.
"What she went on to do was something of a panicky attempt to cover up what she had done initially, so that she could decide on how to rectify it but, the Committee was satisfied, all done with the best of intentions and in the best interests of the cat and its owner.
"She had not acted out of any personal or financial gain or malicious intent.
"She had created a mess and she was trying to sort that mess out.”
After deciding that a reprimand was the most appropriate and proportionate sanction to impose, Paul Morris concluded: “In all the, somewhat exceptional, circumstances of this case, the Committee was satisfied that a reprimand would provide adequate protection to animals, as it was satisfied Dr Parody was most unlikely to ever make such a flawed set of decisions again.
"The Committee was satisfied that Dr Parody does not represent a risk to animals going forward, indeed from the character evidence it is clear that she always puts the welfare of animals first.
"She has also shown, since this episode, that she can work under pressure and not resort to making bad decisions and thus the Committee considered the wider public interest would be served in this case by a reprimand.”
www.rcvs.org.uk/disciplinary
The research is being carried out by James Glass MRCVS (pictured), a PhD researcher working in the Suicide Behaviour Research Lab at the University of Glasgow, supervised by Professor Rory O'Connor - current president of the International Association for Suicide Prevention.
To take part, vets and student vets are being asked to complete a 15-25 minute survey, which must be done in one sitting.
Survey answers are strictly confidential.
Everyone is invited to participate, regardless of whether or not you have experienced suicidal thoughts, however James cautions that some of the questions may be upsetting for anyone currently experiencing suicidal feelings, and emphasises that participants are free to withdraw from the study at any point by closing the webpage, whereupon any answers already submitted with be discarded.
The study is open until 31st December 2024.
https://tinyurl.com/StudyTeamVet
The new clinic will be based in Uttoxeter and have an in-house 1.5T MRI, 32-slice CT, and three purpose-built theatres.
Building work has started and clinic is now recruiting for orthopaedic surgery Specialists, neurology Specialists and experienced veterinary nurses.
Mark Lowrie, RCVS and EBVS European Specialist in Veterinary Neurology (pictured), will lead the new site day-to-day once up and running.
He said: “Our ethos is simple: we aspire to be the place that vets take their own pets.
"By focusing on responsive communication, exceptional clinical standards, and fair pricing, we aim to build trust with both veterinary professionals and clients.
"And for those who join our team, we are committed to creating a supportive and positive environment where everyone can thrive and grow."
“This is a rare chance to be part of something special from day one, to join and help build the culture and success of a dynamic, independent practice and a brand new state-of-the-art clinic.
"With cutting-edge facilities and a supportive team, we want fresh expertise and energy to help shape the future of veterinary care.”
https://www.movementvets.co.uk